Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
This study is a prospective, single-arm, open-label phase II study to evaluate the efficacy and safety of the combination of Utidelone and bevacizumab regimen in patients with ≥ 2 lines of HER-2 negative advanced breast cancer.
HER-2 Negative Breast Cancer
DRUG: Utidelone Combined with Bevacizumab
Objective response rate (ORR), Percentage of patients with a best investigator-assessed response of CR or PR from enrollment until disease progression as assessed by RECIST 1.1 compared with the total number of evaluable patients., up to 2 years
Progression free survival (PFS), PFS is defined as the duration of time from first study treatment to disease progression or death from any cause as documented by the investigator, up to 2 years|Overall survival (OS), OS is defined as the duration of time from first study treatment until death from any cause., up to 3 years
Patients included were patients with ≥ 2 lines of HER2-negative advanced breast cancer who had previously failed taxanes and/or anthracyclines, or patients with hormone receptor-positive HER2-negative advanced breast cancer who had progressed after at least 1 line of prior endocrine therapy.

This study used a Simon two-stage design. 71 subjects will be enrolled using the optimal design.